ATE205400T1 - Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide - Google Patents

Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide

Info

Publication number
ATE205400T1
ATE205400T1 AT93910671T AT93910671T ATE205400T1 AT E205400 T1 ATE205400 T1 AT E205400T1 AT 93910671 T AT93910671 T AT 93910671T AT 93910671 T AT93910671 T AT 93910671T AT E205400 T1 ATE205400 T1 AT E205400T1
Authority
AT
Austria
Prior art keywords
mammal
nonself
polymorphoic
suppression
tolerance
Prior art date
Application number
AT93910671T
Other languages
English (en)
Inventor
Howard L Weiner
David A Hafler
Charles B Carpenter
Mohamed Sayegh
Zhengi Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of ATE205400T1 publication Critical patent/ATE205400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT93910671T 1992-04-20 1993-04-20 Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide ATE205400T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
PCT/US1993/003708 WO1993020842A1 (en) 1992-04-20 1993-04-20 Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (1)

Publication Number Publication Date
ATE205400T1 true ATE205400T1 (de) 2001-09-15

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910671T ATE205400T1 (de) 1992-04-20 1993-04-20 Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide

Country Status (13)

Country Link
US (1) US5593698A (de)
EP (1) EP0637249B1 (de)
JP (1) JPH07505892A (de)
KR (1) KR100275656B1 (de)
AT (1) ATE205400T1 (de)
AU (1) AU686101B2 (de)
BR (1) BR9306345A (de)
CA (1) CA2118502A1 (de)
DE (1) DE69330752D1 (de)
HU (1) HUT71310A (de)
IL (1) IL105472A (de)
NO (1) NO943967L (de)
WO (1) WO1993020842A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
AU2001245848A1 (en) * 2000-03-15 2001-10-23 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
US10137181B2 (en) * 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (de) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistische polypeptide der tumornekrosefaktorrezeptorsuperfamilie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
EP0637249A4 (de) 1997-01-08
DE69330752D1 (de) 2001-10-18
CA2118502A1 (en) 1993-10-28
KR950701228A (ko) 1995-03-23
BR9306345A (pt) 1998-06-30
NO943967D0 (no) 1994-10-19
WO1993020842A1 (en) 1993-10-28
EP0637249A1 (de) 1995-02-08
IL105472A (en) 1999-06-20
JPH07505892A (ja) 1995-06-29
NO943967L (no) 1994-10-19
HU9403006D0 (en) 1994-12-28
IL105472A0 (en) 1993-08-18
KR100275656B1 (ko) 2000-12-15
AU4108393A (en) 1993-11-18
US5593698A (en) 1997-01-14
EP0637249B1 (de) 2001-09-12
AU686101B2 (en) 1998-02-05
HUT71310A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
DE69330752D1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii-spezifische mhc allopeptide
Raff et al. Mouse specific bone marrow-derived lymphocyte antigen as a marker for thymus-independent lymphocytes
PT735893E (pt) Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
Niederwieser et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.
McCoy et al. Leukemia and Lymphoid Tissue-Culture Cells 1, 2
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
GR3033894T3 (en) Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-alpha and histamine, serotonin or substances with corresponding receptor activity.
Dennert Evidence for non-identity of T killer and T helper cells sensitised to allogeneic cell antigens
Thomas et al. IL‐12‐and IL‐2‐induced tumor regression in a new murine model of oral squamous‐cell carcinoma is promoted by expression of the CD80 co‐stimulatory molecule and interferon‐γ
Wagner Cell‐mediated immune response in vitro: Independent differentiation of thymocytes into cytotoxic lymphocytes
Torelli et al. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission
Pape et al. Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon
GR3027668T3 (en) Immunosuppressive compositions
Gallinger et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice
WO2000040701A3 (en) Non-myeloablative tolerogenic treatment
Piatier-Tonneau et al. T suppressor lymphocytes regulation of adjuvant arthritis in two inbred strains of rats
Wimer Immunosuppressive applications of PHA and other plant mitogens
Wersäll et al. Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity
Paranjpe et al. Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay
PT959899E (pt) Anticorpo lo-cd2a e suas utilizações para inibir a activação e proliferação de células t
Rachamim et al. Potential role of CD34 stem cells in tolerance induction
Chen et al. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma
Röllinghoff et al. Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation
Tsokos et al. Concanavalin-induced suppressor cells: characterization on the basis of corticosteroid and radiation sensitivity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties